Under the Paperwork Reduction Act of 1995, no persons are requ

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10770657		
Filing Date		2004-02-03		
First Named Inventor	John	ohn Nelson		
Art Unit		1637		
Examiner Name	Kenn	neth R, Horlick		
Attorney Docket Number		PB0308		

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	tent Number Kind Code1 Issue Date Name of Patentee or Applicar of cited Document			Releva	Columns,Lines was the contract of the contract			
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	 lease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>		Publication Date Name of Patentee or Applicar of cited Document			Releva	Columns,Lines w int Passages or R s Appear	
	1									
If you wisl	h to a	dd additional U.S. Pub		p				d button		
				FOREIG	N PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,L where Relevant Passages or Rele Figures Appear	-
	1	WO02/057447	wo			2002-07-25	GENETICA, INC.		page 11, line 29-pa 12, line 8; page 9, l 26-30; page 100-10 page 112, line 16-2	ine 12;
If you wis	h to a	dd additional Foreign F	atent Do	cument	citation	information p	lease click the Add	button	Add	
			NON	I-PATEN	IT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.							m Ts			

publisher, city and/or country where published.

#### 

1	LIZARDI, P., "Mutation Detection and Single-Molecule Counting Using Isothermal Rolling-Circle Amplification", Nature Genetics, volume 19, July 1999, page 225-232.	

Date Considered

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Petent Documents at Invest USPTO, GOLV or MPEP 96164. I Enter office that issued the document, by the Involvation (WIPO) Standard ST3.) I "For Implanees petent counters, the oricidation of the year of the register or many precede the settle inches of the option that part document. If which office petent document, and occurrent under WIPO Standard ST3. If the possible, "Applicant is to place a check mark here it registed in the petent persistent is standard."

Examiner Signature

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10770657	
Filing Date		2004-02-03	
First Named Inventor	John Nelson		
Art Unit		1637	
Examiner Name	Kenn	eth R. Horlick	
Attorney Docket Number		PB0308	

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication [7] from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(a)(1).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/YONGGANG JI/	Date (YYYY-MM-DD)	2006-09-08
Name/Print	VONGGANG II	Registration Number	53073

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. D. 6th 1450, Alexandria, V.S. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22313-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.